AMGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 308.4 USD | -0.55% |
|
+3.00% | +7.09% |
| 13/05 | Redburn Adjusts Price Target on Amgen to $170 From $180, Keeps Sell Rating | MT |
| 09/05 | ANALYST RECOMMENDATIONS : UBER, Luluemon, Airbnb, Progressive... |  |
ETFs positioned on Amgen Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.23% | 35 M€ | +8.15% | - | |
| 0.23% | 284 M€ | -.--% | ||
| 0.22% | 206 M€ | -.--% | ||
| 0.22% | 571 M€ | +6.88% | - | |
| 0.22% | 0 M€ | 0.00% | - | |
| 0.20% | 391 M€ | +8.67% | - | |
| 0.20% | 7 M€ | +5.61% | - | |
| 0.20% | 32 M€ | +1.38% | - | |
| 0.20% | 17 M€ | +5.61% | - | |
| 0.19% | 34 M€ | +8.24% | - | |
| 0.18% | 1 M€ | -.--% | ||
| 0.17% | 169 M€ | -0.77% | - | |
| 0.16% | 15 M€ | -1.62% | - | |
| 0.16% | 112 M€ | +4.06% | - | |
| 0.14% | 2 M€ | +3.16% | - | |
| 0.14% | 306 M€ | +5.68% | - | |
| 0.14% | 39 M€ | +5.65% | - | |
| 0.13% | 756 M€ | -0.24% | - | |
| 0.12% | 12 M€ | +11.92% | - | |
| 0.10% | 2 M€ | +3.65% | - |
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
308.4
USD
Average target price
314.6
USD
Spread / Average Target
+2.01%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +7.09% | 166B | |
| +29.98% | 684B | |
| +30.34% | 568B | |
| -3.52% | 361B | |
| +18.59% | 329B | |
| +4.07% | 284B | |
| +16.21% | 240B | |
| +9.66% | 208B | |
| -6.83% | 200B | |
| -1.22% | 159B |
- Stock Market
- Equities
- AMGN Stock
- Funds and ETFs Amgen Inc.